[6-[6-[6-[[14,16-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-2-methyl-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl] acetate
17575-21-2CC(=O)OC1CC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CCC5(C)C(C7=CC(=O)OC7)C(O)CC65O)C4)OC3C)OC2C)OC(C)C1OC1OC(CO)C(O)C(O)C1OXVAPNQFQPDAROQ-UHFFFAOYSA-NXVAPNQFQPDAROQ-UHFFFAOYSA-N has been reported in Digitalis lanata with data available.
17575-21-2安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
使用Lanatoside B is a novel cardiac glycoside inhibitor acting on sodium-potassium ATPase in vivo.
純化方法Crystallise lanatoside B from MeOH. Its solubility is: 1/20 (MeOH), 1/40 (EtOH), 1/5600 (CHCl3), and is insoluble in H2O. [Stoll et al. Helv Chim Acta 16 1049 1933, Miyatake et al. Chem Pharm Bull Jpn 5 171 1957, Beilstein 18 III/IV 2465.] It is cardiotonic.
現在のフィルター条件では反応記録がありません。
読み込み中…